ascopubs.org19d
MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with KRAS G12D or KRAS G12V alteration.
Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.
ascopubs.org19d
Sensitizing K-Ras G12D mutant colorectal patient-derived organoids via ferroptosis pathway.
Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...
ascopubs.org9d
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project Incorporating molecular markers into RMS ...
ascopubs.org16d
Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma
The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The ...
ascopubs.org16d
Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial
Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS/NRAS/BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer Females with MBC and any previous lines of therapy ...
ascopubs.org19d
Molecular profiling of a gastroesophageal adenocarcinoma (GEA) multicohort using next-generation sequencing (NGS).
The immunogenomic landscape of primary and metastatic gastroesophageal adenocarcinoma. Exploration of novel biomarkers and novel therapies for immune checkpoint inhibitors (ICIs) in genetic variants ...
ascopubs.org19d
Phase II study of organ preservation (OP) in node-negative (NN) low rectal cancer (RC): Updated clinical and patient reported outcomes (PROs).
A multicenter, prospective phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to anti-EGFR agents (HGCSG1801): Updated analyses. This is an ...
ascopubs.org11d
Patient-Reported Outcomes: Comparing Functional Avoidance and Standard Thoracic Radiation Therapy in Lung Cancer
Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18FDG and 64Cu-DOTA-Trastuzumab ...
ascopubs.org12d
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials Individual patient data of neoadjuvant RCTs ...
ascopubs.org19d
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas Larotrectinib is a ...
ascopubs.org10d
Rethinking the Chosen Eleven
Continued Promise and Possibility of Prospective Payment System Exemption: An Investment in the Future of Cancer Care Innovation An elite club of 11 medical centers started with the introduction of ...
ascopubs.org12d
Aiming Targeted Drug Development at Rare Pediatric Malignancies
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study ...